Metabolism of chylomicron-like emulsions in carriers of the S447X lipoprotein lipase polymorphism

被引:9
作者
Almeida, KA
Schreiber, R
Amâncio, RF
Bydlowski, SP
Debes-Bravo, A
Issa, JS
Strunz, CMC
Maranhao, RC
机构
[1] Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil
[2] InCor, Inst Heart, Lipid Metab Lab, Sao Paulo, SP, Brazil
[3] Univ Sao Paulo, Med Sch Hosp, Dept Hematol, Sao Paulo, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
enzyme mutations; triglycerides; chylomicrons; cholesterol; emulsions; lipoprotein lipase; coronary artery disease;
D O I
10.1016/S0009-8981(03)00289-4
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Lipoprotein lipase catalyzes the hydrolysis of the triglycerides contained in both very-low-density lipoproteins and chylomicrons for storage in the adipose tissue and muscle of fats of both hepatic and dietary origin. The S447X-Stop lipoprotein lipase is the most common polymorphism of the enzyme, affecting roughly 20% of the population and is accompanied by normal or diminished fasting triglycerides and perhaps lower incidence of coronary artery disease (CAD). Delay in the removal of chylomicron and remnant is now an established risk factor for CAD. Methods: Currently, the chylomicron subjects with no mutation. The doubly labeled chylomicron-like emulsion method was used to evaluate chylomicron metabolism. The emulsions labeled with cholesteryl-oleate (C-14-CE) and tri[9,10-H-3]oleate (H-3-Tg) were injected intravenously and the decay curves of the labels were determined by blood sampling over 60 min followed by radioactive counting. Results: The fractional clearance rate (FCR, min(-1)) of the labels was not different in the S447X carriers compared with the noncarriers (FCR H-3-Tg 0.035 +/- 0.019 and 0.030 +/- 0.009; FCR C-14-CE 0.008 +/- 0.007 and 0.009 +/- 0.007, respectively). Conclusions: The chylomicron intravascular lipolysis monitored by the H-3-Tg emulsion and the remnant removal monitored by the C-14-CE emulsion were not altered by the presence of this polymorphism of great populational impact. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 34 条
[1]   MALIGNANT HYPERTENSION IS ACCOMPANIED BY MARKED ALTERATIONS IN CHYLOMICRON METABOLISM [J].
BERNARDESSILVA, H ;
TOFFOLETTO, O ;
BORTOLOTTO, LA ;
LATRILHA, MCM ;
KRIEGER, EM ;
PILEGGI, F ;
MARANHAO, RC .
HYPERTENSION, 1995, 26 (06) :1207-1210
[2]  
Borba EF, 2000, ARTHRITIS RHEUM, V43, P1033, DOI 10.1002/1529-0131(200005)43:5<1033::AID-ANR11>3.0.CO
[3]  
2-B
[4]  
Cooper AD, 1997, J LIPID RES, V38, P2173
[5]  
FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418
[6]   Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis [J].
Fisher, RM ;
Humphries, SE ;
Talmud, PJ .
ATHEROSCLEROSIS, 1997, 135 (02) :145-159
[7]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[8]   A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease:: the Framingham Offspring Study [J].
Gagné, SE ;
Larson, MG ;
Pimstone, SN ;
Schaefer, EJ ;
Kastelein, JJP ;
Wilson, PWF ;
Ordovas, JM ;
Hayden, MR .
CLINICAL GENETICS, 1999, 55 (06) :450-454
[9]  
Goldberg IJ, 1996, J LIPID RES, V37, P693
[10]   Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients - The Ser(447)-Stop substitution in the lipoprotein lipase gene [J].
Groenemeijer, BE ;
Hallman, MD ;
Reymer, PWA ;
Gagne, E ;
Kuivenhoven, JA ;
Bruin, T ;
Jansen, H ;
Lie, KI ;
Bruschke, AVG ;
Boerwinkle, E ;
Hayden, MR ;
Kastelein, JJP .
CIRCULATION, 1997, 95 (12) :2628-2635